Search Results

A team of investigators at City of Hope funded by the Prostate Cancer Foundation reports that patients with advanced prostate cancer can be safely treated with chimeric antigen receptor T cell therapy.

Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It helps AstraZeneca position itself as a top player in the prostate cancer space, alongside its Big Pharma colleagues.

The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, potentially covering all patients with metastatic castration-resistant prostate cancer regardless of biomarker status.

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, detailed data presented by its partners at the University of California, San Francisco on foundational prostate cancer antigen research utilized to inform the development of its mRNA drug candidate, NTX-470.

Candel’s trial was conducted under the FDA’s Special Protocol Assessment program, meaning that its data could be used as a basis for a regulatory application.

Telix Pharmaceuticals Limited announces it has submitted a New Drug Application to the United States Food and Drug Administration for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging1 for prostate cancer.